治疗全身性青少年异常性关节炎的治疗方法
Claas H Hinze1, Dirk Foell2, Christoph Kessel1
1Department of Paediatric Rheumatology and Immunology, Münster University Hospital, Münster, Germany.
Nature reviews. Rheumatology
|November 4, 2023
概括
系统性青少年异常性关节炎 (SJIA) 是一种严重的炎症性疾病. 本综述详细介绍了sJIA及其并发症的当前治疗方法,强调了最佳患者护理的知识差距.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 系统性青少年异常性关节炎 (SJIA) 是儿童的一种严重的炎症性疾病,与成人发病的斯蒂尔病 (AOSD) 有共同特征.
- 患有sJIA的患者面临严重并发症的风险,如巨细胞激活综合征 (sJIA-MAS) 和肺部疾病 (sJIA-LD).
- 目前对sJIA的治疗方法已经进步,包括针对IL-1和IL-6通路的生物药物.
研究的目的:
- 审查目前对sJIA,sJIA-MAS和sJIA-LD的治疗策略.
- 识别和讨论管理sJIA的知识差距,特别是早期或耐火病例.
- 为SJIA提供新兴疗法的前景.
主要方法:
- 对sJIA的当代科学见解和治疗方法的文献综述.
- 分析当前的共识治疗计划及其局限性.
- 讨论新药和未来的研究方向.
主要成果:
- 针对IL-1和IL-6的生物药物是当前的护理标准.
- 新兴疗法包括JAK抑制剂和向IL-18,IFNγ或IL-1β/IL-18的生物药物.
- 早期,耐火性或复杂的sJIA的治疗方法仍然不那么明确.
结论:
- 虽然sJIA的治疗方法有所改善,但在管理复杂病例和并发症方面仍然存在挑战.
- 需要进一步的研究来确定所有sJIA患者子组的最佳策略.
- 对目前和未来的疗法有全面的了解,对于世界各地的风湿病学家来说至关重要.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
01:29Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
01:26Tonsillitis II: Management
120
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
120
01:17Pericarditis III: Medical Management
13
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
13
01:20Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K